| Demographics |
| Age, years, median (IQR) |
62 |
(23.5) |
60.5 |
(17) |
| Female sex, n (%) |
19 |
(76%) |
15 |
(68.2%) |
| Race, n (%) |
| White |
15 |
(60%) |
15 |
(68.2%) |
| Hispanic |
6 |
(24%) |
1 |
(4.5%) |
| Asian/Pacific Islander |
1 |
(4%) |
5 |
(22.7%) |
| African American |
0 |
(0%) |
1 |
(4.5%) |
| Other |
3 |
(12%) |
0 |
0 |
|
| Non-invasive clinical metrics |
| NYHA functional class, n (%) |
| Class I or II |
13 |
(52%) |
|
|
| Class III |
10 |
(40%) |
|
|
| Class IV |
2 |
(8%) |
|
|
| Six minute walk distance, m, median (IQR) |
422 |
(207) |
|
|
| NT-proBNP, pg/ml, median (IQR) |
129 |
(398) |
|
|
| DLCO, % of predicted, median (IQR) |
72 |
(30) |
|
|
|
| RHC hemodynamic measurements |
| Mean pulmonary arterial pressure, mm Hg, median (IQR) |
40 |
(14) |
|
|
| Pulmonary vascular resistance, Wood units, median (IQR) |
7.75 |
(6.2) |
|
|
| Mean right atrial pressure, mm Hg, median (IQR) |
9 |
(6) |
|
|
| Cardiac index, ml/min/m2, median (IQR) |
2.19 |
(0.49) |
|
|
|
| Background PAH guided therapy |
| Number of agents, n (%) |
| Treatment naïve |
8 |
(32%) |
|
|
| Monotherapy |
9 |
(36%) |
|
|
| Dual therapy |
4 |
(16%) |
|
|
| Triple therapy |
4 |
(16%) |
|
|
| Class of agents, n (%) |
| Phosphodiesterase-5 inhibitor |
12 |
(48%) |
|
|
| Endothelin receptor antagonist |
6 |
(24%) |
|
|
| Prostanoid |
11 |
(44%) |
|
|
